| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/16/1993 | CA1314480C Mouldings made from pellets |
| 03/10/1993 | EP0530995A1 Lozenges |
| 03/10/1993 | EP0524987A4 Eriodictyon drug delivery systems |
| 03/10/1993 | EP0417191B1 Formulation for antibody reagents |
| 03/10/1993 | EP0365519B1 Topical prodrugs for treatment of acne and skin diseases |
| 03/10/1993 | EP0312581B1 Pharmaceutical sustained release matrix and process |
| 03/10/1993 | CN1069741A Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
| 03/09/1993 | US5192784 Physical and chemical stability |
| 03/09/1993 | US5192743 Topical gel mixture with glycerol, tissue factor, and cellulose ether |
| 03/09/1993 | US5192741 Sustained and controlled release of water insoluble polypeptides |
| 03/09/1993 | US5192577 Nutritional composition and a process for its production |
| 03/09/1993 | US5192552 Process for preparing microcapsules providing the rapid release of a drug as active ingredient |
| 03/09/1993 | US5192535 Ophthalmic suspensions |
| 03/09/1993 | CA1314245C Process for the preparation of conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule, which are useful as immunotoxin potentiators |
| 03/09/1993 | CA1314231C Ifosphamide lyophilisate and process for its preparation |
| 03/09/1993 | CA1314230C Mixtures for treating hypercholesterolemia |
| 03/09/1993 | CA1314227C Pharmaceutical composition containing ketotifen |
| 03/09/1993 | CA1314225C Controlled release agent for cetylpyridinium chloride |
| 03/09/1993 | CA1314217C Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals |
| 03/09/1993 | CA1314213C Phospholipid delivery vehicle for aqueous-insoluble active ingredients |
| 03/09/1993 | CA1314212C Stable parmaceutical w/o emulsion composition |
| 03/05/1993 | CA2062303A1 Method of preparation of nanocapsules |
| 03/04/1993 | WO1993004191A1 Noncytolytic toxin conjugates |
| 03/04/1993 | WO1993004085A1 Anti-hiv proteins gap 31, dap 30 and dap 32, dna coding therefor and therapeutic uses thereof |
| 03/04/1993 | WO1993004082A1 Analogs of hirudin |
| 03/04/1993 | WO1993003769A1 Adenovirus mediated transfer of genes to the gastrointestinal tract |
| 03/04/1993 | WO1993003767A1 Improved transdermal formulations |
| 03/04/1993 | WO1993003765A1 Escherichia coli o-polysaccharide-protein conjugate vaccine |
| 03/04/1993 | WO1993003764A1 Hla-restricted hepatitis b virus ctl epitopes |
| 03/04/1993 | WO1993003751A1 Compositions and methods for the sublingual or buccal administration of therapeutic agents |
| 03/04/1993 | WO1993003747A1 STABILIZED IL-1α PHARMACEUTICAL PREPARATION |
| 03/04/1993 | WO1993003745A1 Method of producing well tolerated drugs containing human proteins for administration by infusion or injection |
| 03/04/1993 | WO1993003744A1 Process for producing preserved medicaments containing human proteins for the purposes of infusion or injection |
| 03/04/1993 | WO1993003739A1 Biocompatible and biodegradable poly(phosphoester-urethanes) |
| 03/04/1993 | WO1993003731A1 Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
| 03/04/1993 | WO1993003723A1 Leukotriene receptor antagonist-antihistamine complex |
| 03/04/1993 | WO1993003709A1 Composition and method for treating cystic fibrosis |
| 03/04/1993 | WO1993003697A1 Transdermal formulations for administering prazosin |
| 03/04/1993 | WO1993003694A1 Transdermal administration of short or intermediate half-life benzodiazepines |
| 03/04/1993 | DE4211883C1 Stable, heat-sterilisable carbamazepine soln. for parenteral admin. - comprises carbamazepine dissolved in tetra:hydro:furfuryl alcohol, polyethylene glycol ether, water and polyvinyl pyrrolidone |
| 03/04/1993 | DE4129309A1 Liq. dosage forms of sparingly soluble drug e.g. ciprofloxacin - contain alkyl lactam as adjuvant, opt. surfactant, pref., e.g. fatty acid and/or miscible diluent |
| 03/04/1993 | DE4128693A1 Oel-in-wasser-emulsionen polarer oelkomponenten Oil-in-water emulsions-polar oelkomponenten |
| 03/04/1993 | DE4120760A1 Traegersysteme fuer arzneimittel Carrier systems for drug |
| 03/04/1993 | CA2145382A1 Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy |
| 03/04/1993 | CA2116359A1 Anti-hiv proteins gap 31, dap 30, and dap 32, dna coding therefor and therapeutic uses thereof |
| 03/04/1993 | CA2115841A1 Transdermal administration of short or intermediate half-life benzodiazepines |
| 03/04/1993 | CA2115840A1 Transdermal formulation for administering prazosin |
| 03/04/1993 | CA2115831A1 Improved transdermal formulations |
| 03/04/1993 | CA2115742A1 Adenovirus mediated transfer of genes to the gastrointestinal tract |
| 03/04/1993 | CA2115364A1 Composition and method for treating cystic fibrosis |
| 03/04/1993 | CA2114945A1 Leukotriene receptor antagonist-antihistamine complex |
| 03/03/1993 | EP0530060A1 Medication based on neutralised sulphur derivatives |
| 03/03/1993 | EP0529175A1 Conjugates chelated with paramagnetic metals for targetting |
| 03/03/1993 | EP0529123A1 Pharmaceutical preparation for percutaneous absorption |
| 03/03/1993 | EP0528978A1 Controlled release dopamine and its use to stimulate nerve fiber growth |
| 03/03/1993 | EP0528891A1 Method for increasing blood-brain barrier permeability |
| 03/03/1993 | EP0528862A1 Composition for solid pharmaceutical preparations containing vitamin d 3? derivative and process for preparation thereof |
| 03/03/1993 | EP0443007A4 An external analgesic lotion and method of making |
| 03/03/1993 | EP0390930B1 Stable aqueous preparation of active vitamin d 3 |
| 03/03/1993 | CN1069409A Process technology of medicine containing adhesive component |
| 03/03/1993 | CN1069408A Pharmaceuctical spheroid formulation |
| 03/02/1993 | US5191067 For treatment of fibroblast growth factor mediated pathophysiological conditions |
| 03/02/1993 | US5190865 Antibody-enhanced stereospecific hydrolyses |
| 03/02/1993 | US5190822 Surface-modifiable liposome and process for producing surface-modified liposome |
| 03/02/1993 | US5190758 Sebaceous excitosecretory agent |
| 03/02/1993 | US5190748 Cephalosporins with ethylene oxide fatty alcohol derivatives and caprylic acid salts |
| 02/24/1993 | EP0528604A1 Melt cocrystallized sorbitol/xylitol compositions |
| 02/24/1993 | EP0528527A2 Conjugates |
| 02/24/1993 | EP0528314A1 Process for the preparation of bearable medicine containing an human protein for injection or infusion |
| 02/24/1993 | EP0528313A1 Process for the preparation of a preserved medicine containing an human protein for injection of infusion |
| 02/24/1993 | EP0528011A1 CD4-GAMMA2 AND CD4-IgG2 CHIMERAS |
| 02/24/1993 | EP0527954A1 Molecular recognition units |
| 02/24/1993 | EP0527946A1 Controlled release vehicle. |
| 02/24/1993 | EP0527942A1 Colonic drug delivery system |
| 02/24/1993 | EP0527891A1 Biodegradable polyesters for sustained drug delivery. |
| 02/24/1993 | EP0527840A1 Non-destructive carriers for cyclodextrin complexes |
| 02/24/1993 | EP0527781A1 Methods and formulations for stabilizing fibroblast growth factor |
| 02/24/1993 | EP0527735A1 Cholesterol removal |
| 02/24/1993 | EP0510132A4 Polymeric carriers for release of covalently linked agents |
| 02/24/1993 | EP0502949A4 Homologous guluronic acid alginate coating composition for in-vivo application and implantation and method of using same |
| 02/24/1993 | CN1069191A Pharmaceutical combination formulation |
| 02/23/1993 | WO1993003741A1 Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy |
| 02/23/1993 | US5189204 Optical active 3-(2-trifluoro-1-hydroxyethyl) propenyl benzyl ether, derivatives thereof, method for preparing the same and use thereof for liquid crystal compound |
| 02/23/1993 | US5189149 High concentration, solvent-free |
| 02/23/1993 | US5189148 Fibroblast growth factor; mixture with water insoluble hydroxypropyl cellulose |
| 02/23/1993 | US5189022 Using polypeptide |
| 02/23/1993 | US5188842 Heating and concentrating aqueous composition containing heat denaturable protein, forming microcolloidal particles |
| 02/23/1993 | US5188841 Sustained release pharmaceutical formulations |
| 02/23/1993 | US5188840 Slow-release pharmaceutical agent |
| 02/23/1993 | US5188836 Release in both the stomach and small intestines; multilayer coating |
| 02/23/1993 | US5188833 Antibacterial quinolinecarboxylic acid derivatives; photostability, heat resistance |
| 02/23/1993 | US5188826 Used for dry eye application, consists of crosslinked acrylic acid polymer, one or more demulcents and vasoconstrictors; administered to eye in drop or gel form and releases water |
| 02/23/1993 | US5188825 Freeze-dried dosage forms and methods for preparing the same |
| 02/20/1993 | CA2076273A1 Coating composition for parts |
| 02/18/1993 | WO1993003035A1 Anti-hiv drug |
| 02/18/1993 | WO1993002712A1 Preparation of microparticles |
| 02/18/1993 | WO1993002709A1 Receptor conjugates for targeting drugs and other agents |
| 02/18/1993 | WO1993002708A1 Novel reagent for tumour imaging and therapy |
| 02/18/1993 | WO1993002703A1 Prodrugs activated by targeted catalytic proteins |
| 02/18/1993 | WO1993002701A1 Buffered formulation of peg-sod |